Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A.R.R.O.W.2: Once-weekly vs twice-weekly carfilzomib + lenalidomide + dexamethasone in relapsed/refractory multiple myeloma
2018-000665-36Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2018
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carfilzomib in multiple myeloma (MM) (2 arms), sponsored by Amgen. Primary endpoint: Overall response rate. Started Dec 2018; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-000665-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000665-36.